OrganiGram Holdings

OrganiGram Holdings Inc is a licensed producer of medical marijuana in Canada, operating under the Marihuana for Medical Purposes Regulations (MMPR). The company focuses on producing high-quality, indoor-grown cannabis for both medical patients and adult recreational consumers. OrganiGram has developed a diverse portfolio of recreational cannabis brands, including Edison, Big Bag o' Buds, SHRED, Monjour, Holy Mountain, and Trailblazer. Recently, the company expanded its offerings to include Tremblant Cannabis and the artisanal craft brand Laurentian, enhancing its brand presence in the competitive cannabis market.

Nathalie Batten

Senior Vice President

Past deals in Cannabis

Hyasynth

Debt Financing in 2021
Hyasynth Bio is a Montreal-based company that specializes in the production of natural cannabinoid compounds. It focuses on developing innovative solutions for researchers, healthcare professionals, and patients dealing with conditions such as multiple sclerosis, epilepsy, Alzheimer's disease, chronic pain, inflammation, and muscular dystrophy. By leveraging a combination of traditional and modern biological technologies along with computational analysis, Hyasynth Bio aims to create effective drugs for a wide range of diseases. The company utilizes a scalable platform based on engineered microbes to enhance its drug development process, effectively addressing the needs of the medical community.

Edibles & Infusions

Acquisition in 2021
Edibles & Infusions is a cannabis processor and soft chew manufacturer.

Hyasynth

Corporate Round in 2020
Hyasynth Bio is a Montreal-based company that specializes in the production of natural cannabinoid compounds. It focuses on developing innovative solutions for researchers, healthcare professionals, and patients dealing with conditions such as multiple sclerosis, epilepsy, Alzheimer's disease, chronic pain, inflammation, and muscular dystrophy. By leveraging a combination of traditional and modern biological technologies along with computational analysis, Hyasynth Bio aims to create effective drugs for a wide range of diseases. The company utilizes a scalable platform based on engineered microbes to enhance its drug development process, effectively addressing the needs of the medical community.

Hyasynth

Corporate Round in 2018
Hyasynth Bio is a Montreal-based company that specializes in the production of natural cannabinoid compounds. It focuses on developing innovative solutions for researchers, healthcare professionals, and patients dealing with conditions such as multiple sclerosis, epilepsy, Alzheimer's disease, chronic pain, inflammation, and muscular dystrophy. By leveraging a combination of traditional and modern biological technologies along with computational analysis, Hyasynth Bio aims to create effective drugs for a wide range of diseases. The company utilizes a scalable platform based on engineered microbes to enhance its drug development process, effectively addressing the needs of the medical community.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.